2026-07-21T08:13:14Zhttps://repisalud.isciii.es/rest/oai/requestoai:repisalud.isciii.es:20.500.12105/148692025-04-30T12:44:36Zcom_20.500.12105_2052com_20.500.12105_2051col_20.500.12105_19609
Repisalud
author
Galán Burgos, Miguel
author
Vigon-Hernandez, Lorena
author
Fuertes, Daniel
author
Murciano-Antón, María Aranzazu
author
Casado-Fernández, Guiomar
author
Domínguez-Mateos, Susana
author
Mateos, Elena
author
Ramos-Martín, Fernando
author
Planelles, Vicente
author
Torres, Montserrat
author
Rodriguez Mora, Sara
author
Lopez-Huertas, Maria Rosa
author
Coiras, Mayte
author
Multidisciplinary Group of Study of COVID-19 (MGS-COVID)
funder
Instituto de Salud Carlos III
funder
Ministerio de Ciencia e Innovación (España)
funder
Unión Europea. Fondo Europeo de Desarrollo Regional (FEDER/ERDF)
funder
National Institutes of Health (Estados Unidos)
funder
Chiesi Foundation
funder
Red de Investigación Cooperativa en Investigación en Sida (España)
2022-08-05T11:23:32Z
2022-08-05T11:23:32Z
2022-03-25
Front Immunol. 2022 Mar 25;13:848886.
10.3389/fimmu.2022.848886
1664-3224
Frontiers in Immunology
35401523
http://hdl.handle.net/20.500.12105/14869
Long-COVID is a new emerging syndrome worldwide that is characterized by the persistence of unresolved signs and symptoms of COVID-19 more than 4 weeks after the infection and even after more than 12 weeks. The underlying mechanisms for Long-COVID are still undefined, but a sustained inflammatory response caused by the persistence of SARS-CoV-2 in organ and tissue sanctuaries or resemblance with an autoimmune disease are within the most considered hypotheses. In this study, we analyzed the usefulness of several demographic, clinical, and immunological parameters as diagnostic biomarkers of Long-COVID in one cohort of Spanish individuals who presented signs and symptoms of this syndrome after 49 weeks post-infection, in comparison with individuals who recovered completely in the first 12 weeks after the infection. We determined that individuals with Long-COVID showed significantly increased levels of functional memory cells with high antiviral cytotoxic activity such as CD8+ TEMRA cells, CD8±TCRγδ+ cells, and NK cells with CD56+CD57+NKG2C+ phenotype. The persistence of these long-lasting cytotoxic populations was supported by enhanced levels of CD4+ Tregs and the expression of the exhaustion marker PD-1 on the surface of CD3+ T lymphocytes. With the use of these immune parameters and significant clinical features such as lethargy, pleuritic chest pain, and dermatological injuries, as well as demographic factors such as female gender and O+ blood type, a Random Forest algorithm predicted the assignment of the participants in the Long-COVID group with 100% accuracy. The definition of the most accurate diagnostic biomarkers could be helpful to detect the development of Long-COVID and to improve the clinical management of these patients.
eng
CD8+ T cells
Long-COVID
NK cells
Random Forest algorithm
Cytotoxic immune response
Immune exhaustion
Persistent Overactive Cytotoxic Immune Response in a Spanish Cohort of Individuals With Long-COVID: Identification of Diagnostic Biomarkers
research article
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
URL
https://repisalud.isciii.es/bitstreams/8250aba6-d182-4bd0-9694-b9c303d14dbb/download
File
MD5
6acfdcbc5d8ec590a6ef38323492fada
2593412
application/pdf
PersistentOveractiveCytotoxicImmune_2022.pdf
URL
https://repisalud.isciii.es/bitstreams/29e7302d-67f3-4281-823a-3708618510e3/download
File
MD5
62e2360830719caed94a8715c7b4ba6d
339096
application/pdf
PersistentOveractiveCytotoxicImmunePresentation1_2022.pdf
URL
https://repisalud.isciii.es/bitstreams/919b4cc6-430c-42c5-aa8f-1a288f2a5bdf/download
File
MD5
9b696481d67f0576e82b9007c031c1a7
245272
application/pdf
PersistentOveractiveCytotoxicImmunePresentation2_2022.pdf
URL
https://repisalud.isciii.es/bitstreams/5ee4dc63-d097-4361-b5a1-6b51b011bb95/download
File
MD5
ebc292dded4f9d207b00fb212f059dc1
141398
application/pdf
PersistentOveractiveCytotoxicImmunePresentation3_2022.pdf
URL
https://repisalud.isciii.es/bitstreams/bd786ff0-4784-414b-bce2-448078c8f536/download
File
MD5
dc8be309f470968871d02352fea786b8
174065
application/pdf
PersistentOveractiveCytotoxicImmunePresentation4_2022.pdf
URL
https://repisalud.isciii.es/bitstreams/203ad2e8-0867-4cc0-906d-86f661f89401/download
File
MD5
6d581b902d24c4b94f72d6a627aec508
296932
application/pdf
PersistentOveractiveCytotoxicImmuneTable1_2022.pdf
URL
https://repisalud.isciii.es/bitstreams/d30c3089-5c13-47d0-807d-3f1dab9b5160/download
File
MD5
6d581b902d24c4b94f72d6a627aec508
296932
application/pdf
PersistentOveractiveCytotoxicImmuneTable1_2022.pdf
URL
https://repisalud.isciii.es/bitstreams/131bce48-e298-4907-9e5b-b6993a39beaf/download
File
MD5
6392cc449ab4185090193f26e99a6030
66839
text/plain
PersistentOveractiveCytotoxicImmune_2022.pdf.txt
URL
https://repisalud.isciii.es/bitstreams/65d60847-fcd6-4edf-811f-354e4869dac6/download
File
MD5
337ce17f59866a5c3eec24f67ac7128f
253
text/plain
PersistentOveractiveCytotoxicImmunePresentation1_2022.pdf.txt
URL
https://repisalud.isciii.es/bitstreams/ea1bb8c6-433c-427b-9648-2ff870437709/download
File
MD5
4208e542e99a49cd57121bcdf86f0569
222
text/plain
PersistentOveractiveCytotoxicImmunePresentation2_2022.pdf.txt
URL
https://repisalud.isciii.es/bitstreams/aade47ce-3556-4d09-a1ea-26103a6fff40/download
File
MD5
7c7a391c9a763874144fd0fdb9943a9d
230
text/plain
PersistentOveractiveCytotoxicImmunePresentation3_2022.pdf.txt
URL
https://repisalud.isciii.es/bitstreams/b40e327e-f9ca-4d69-95fe-b4acf3a33c0a/download
File
MD5
3a67f15b721ef7d1f6520120cd09b730
171
text/plain
PersistentOveractiveCytotoxicImmunePresentation4_2022.pdf.txt
URL
https://repisalud.isciii.es/bitstreams/b50f52ef-5f99-43e7-af33-3391ad8e75ae/download
File
MD5
81bc2615433e79a393120b935fc4da2b
11567
text/plain
PersistentOveractiveCytotoxicImmuneTable1_2022.pdf.txt